Close

Pre-Open Movers: Nielsen Climbs 20%, AppLivin Makes Offer for Unity

August 9, 2022 8:50 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

BBQ Holdings Inc. (NASDAQ: BBQ) +46%; entered into a definitive merger agreement under which MTY would acquire all of the issued and outstanding common shares of BBQ Holdings for cash consideration of US$17.25 per BBQ Holdings share representing total transaction value of approximately US$200 million (C$257 million) (the “Transaction”), including BBQ Holdings’ net debt.

GoodRx Holdings, Inc. (NASDAQ: GDRX) +30%; Revenue for the quarter came in at $191.8 million versus the consensus estimate of $185.36 million.

Helbiz (NASDAQ: HLBZ) climbs 30%.

Nielsen Holdings (NYSE: NLSN) +21%; announced that the court meeting and the special meeting of its shareholders due to be held today have been postponed. The purpose of the Meetings was to consider and vote on proposals to give effect to the transaction contemplated by the previously announced definitive agreement for the Company to be acquired by a private equity consortium (the "Consortium") composed of Evergreen Coast Capital Corp., an affiliate of Elliott Investment Management L.P., and Brookfield Business Partners L.P. together with other institutional partners (collectively "Brookfield").

Mersana Therapeutics (NASDAQ: MRSN) +18%; announced a global collaboration that provides GSK plc an exclusive option to co-develop and commercialize XMT-2056, an Immunosynthen ADC that targets a novel epitope of HER2. XMT-2056 is designed to activate the innate immune system through STING signaling in both tumor-resident immune cells and in tumor cells.

Lemonade (NYSE: LMND) +13%; reported Q2 EPS of ($1.10), $0.23 better than the analyst estimate of ($1.33). Revenue for the quarter came in at $50 million versus the consensus estimate of $47.56 million.GUIDANCE: Lemonade sees Q3 2022 revenue of $63-65 million, versus the consensus of $56.98 million. Lemonade sees FY2022 revenue of $236-239 million, versus the consensus of $214.67 million.

AIkido Pharma (NASDAQ: AIKI) +7%; Shalom Auerbach, a significant stockholder of AIkido Pharma Inc. (NASDAQ: AIKI) (“AIKI” or the “Company”) beneficially owning approximately 3.8% of its common stock, today announced that he has sent a letter proposing to acquire the Company for $8.00 per share in cash.

Unity Software Inc. (NYSE: U) +7% ; AppLovin (NASDAQ: APP) today announced it has submitted a compelling non-binding proposal to the Board of Directors of Unity Software Inc. (NYSE: U) to combine AppLovin, a leader in mobile marketing and monetization, with Unity, an industry leading platform for creating and operating interactive, real-time 3D (RT3D) content, in a transaction where each outstanding share of Unity common stock would be exchanged for 1.152 shares of AppLovin Class A voting common stock and 0.314 shares of AppLovin Class C non-voting common stock.

CorMedix (NASDAQ: CRMD) -60%; today announced updates related to the FDA review of the DefenCath New Drug Application (NDA) as well as other manufacturing and commercial updates. A second Complete Response Letter (CRL) was received from the FDA stating that the DefenCath NDA cannot be approved until deficiencies recently conveyed to the contract manufacturing organization (CMO) and the supplier of the active pharmaceutical ingredient (API) heparin during inspections are resolved to the satisfaction of FDA.

Novavax (NASDAQ: NVAX) -32%; Novavax (NASDAQ: NVAX) reported Q2 EPS of ($6.53), $12.03 worse than the analyst estimate of $5.50. Revenue for the quarter came in at $186 billion versus the consensus estimate of $1.02 billion. GUIDANCE: Novavax sees FY2022 revenue of $2-2.3 billion, versus the consensus of $4.27 billion.

TaskUs, Inc. (NASDAQ: TASK) -16%; reported Q2 EPS of $0.38, $0.05 better than the analyst estimate of $0.33. Revenue for the quarter came in at $246.5 million versus the consensus estimate of $242.11 million. GUIDANCE: TaskUs, Inc. sees Q3 2022 revenue of $224-226 million, versus the consensus of $244 million. TaskUs, Inc. sees FY2022 revenue of $930-950 million, versus the consensus of $992 million.

CarGurus (NASDAQ: CARG) -15%; reported Q2 EPS of $0.32, $0.01 better than the analyst estimate of $0.31. Revenue for the quarter came in at $511.2 million versus the consensus estimate of $507.32 million. GUIDANCE: CarGurus sees Q3 EPS of $0.25-$0.28, versus the consensus of $0.33. CarGurus sees Q3 revenue of $460-490 million, versus the consensus of $554.6 million.

3D Systems (NYSE: DDD) -13% ; reported Q2 EPS of ($0.07), $0.07 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $140 million versus the consensus estimate of $146.8 million. GUIDANCE: 3D Systems sees 2022 revenue of $530-570 million, versus the consensus of $598 million.

Allbirds, Inc. (NASDAQ: BIRD) -13%; reported Q2 EPS of ($0.12), $0.04 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $78.2 million versus the consensus estimate of $77.8 million. GUIDANCE: Allbirds, Inc. sees FY2022 revenue of $305-315 million, versus the consensus of $339.6 million.

Trex (NYSE: TREX) -12%; reported Q2 EPS of $0.79, $0.12 better than the analyst estimate of $0.67. Revenue for the quarter came in at $386 million versus the consensus estimate of $381.1 million. GUIDANCE: Trex sees Q3 2022 revenue of $185-195 million, versus the consensus of $354.82 million. Trex sees FY2022 revenue of $1.09-1.11 billion, versus the consensus of $1.38 billion.

Norwegian Cruise Line (NYSE: NCLH) -9%; reported Q2 EPS of ($1.14), $0.26 worse than the analyst estimate of ($0.88). Revenue for the quarter came in at $1.19 billion versus the consensus estimate of $1.26 billion. Outlook: Total revenue is expected to be $1.5-$1.6 billion in the third quarter of 2022 vs consensus of $1.88 billion)



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Definitive Agreement, Pre Market Movers, FDA